Insider Selling: Natera, Inc. (NASDAQ:NTRA) Insider Sells 787 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) insider Daniel Rabinowitz sold 787 shares of the company’s stock in a transaction on Tuesday, April 23rd. The stock was sold at an average price of $91.38, for a total transaction of $71,916.06. Following the completion of the transaction, the insider now directly owns 205,552 shares of the company’s stock, valued at approximately $18,783,341.76. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Daniel Rabinowitz also recently made the following trade(s):

• On Thursday, February 29th, Daniel Rabinowitz sold 20,526 shares of Natera stock. The stock was sold at an average price of $89.01, for a total transaction of $1,827,019.26.
• On Tuesday, February 27th, Daniel Rabinowitz sold 35,307 shares of Natera stock. The stock was sold at an average price of $75.09, for a total transaction of $2,651,202.63.

Natera Stock Performance

NASDAQ:NTRA opened at $91.04 on Wednesday. The stock’s fifty day moving average is $86.40 and its 200 day moving average is $66.49. Natera, Inc. has a fifty-two week low of $36.90 and a fifty-two week high of $98.82. The firm has a market capitalization of $10.99 billion, a PE ratio of -24.02 and a beta of 1.37. The company has a debt-to-equity ratio of 0.37, a quick ratio of 3.96 and a current ratio of 4.10.

Natera (NASDAQ:NTRA) last released its earnings results on Wednesday, February 28th. The medical research company reported ($0.64) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.09. Natera had a negative return on equity of 62.19% and a negative net margin of 40.16%. The business had revenue of $311.11 million for the quarter, compared to analyst estimates of $300.38 million. On average, sell-side analysts anticipate that Natera, Inc. will post -2.35 earnings per share for the current year.

Institutional Trading of Natera

Hedge funds and other institutional investors have recently bought and sold shares of the business. RiverPark Advisors LLC purchased a new stake in Natera in the fourth quarter worth $27,000. Principal Securities Inc. purchased a new stake in Natera in the fourth quarter worth $32,000. Harvest Fund Management Co. Ltd purchased a new stake in Natera in the third quarter worth $44,000. Oliver Lagore Vanvalin Investment Group increased its stake in Natera by 109.3% in the fourth quarter. Oliver Lagore Vanvalin Investment Group now owns 745 shares of the medical research company’s stock worth $47,000 after purchasing an additional 389 shares during the period. Finally, Arcadia Investment Management Corp MI increased its stake in Natera by 47.8% in the first quarter. Arcadia Investment Management Corp MI now owns 538 shares of the medical research company’s stock worth $49,000 after purchasing an additional 174 shares during the period. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have commented on NTRA. Craig Hallum began coverage on shares of Natera in a research note on Monday, April 8th. They issued a “buy” rating and a $117.00 price target on the stock. StockNews.com cut shares of Natera from a “hold” rating to a “sell” rating in a research note on Tuesday. The Goldman Sachs Group boosted their price target on shares of Natera from $90.00 to $100.00 and gave the stock a “buy” rating in a research note on Monday, April 15th. Sanford C. Bernstein upgraded shares of Natera from a “market perform” rating to an “outperform” rating and set a $120.00 target price on the stock in a research report on Friday, April 5th. Finally, Piper Sandler lifted their price target on Natera from $70.00 to $110.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 6th. One research analyst has rated the stock with a sell rating and fourteen have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $86.40.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.